1. HBW Insight
  2. >>Leadership

Perrigo’s Next CEO Has Long OTC Brands History

Lockwood-Taylor Moves From Bayer As Perrigo Awaits Decision On OTC Oral Contraceptive

 
• By Malcolm Spicer

Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.

• Source: Shutterstock

Perrigo Company PLC’s transition from leading the OTC drug private label/store brand space to also competing in branded consumer health product sales will be in the hands of an industry veteran with experience at two firms behind some of the most well-known global brands.

Perrigo firm on 8 June announced Patrick Lockwood-Taylor will start as president and CEO on 30 June,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By David Ridley

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

Makary’s Reorganization Decision A Turning Point For US FDA?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel

 
• By Sue Sutter and Derrick Gingery

Alonza Cruse, director of the Office of Human and Animal Drugs Inspectorate, and two other senior inspection officials are departing, along with Mark Raza, chief counsel from 2021 until January.

More from HBW Insight

Global Alliance Urges UN General Assembly To Put Self-Care At Centre Of NCD Strategy

 
• By David Ridley

Including self-care in an upcoming UN General Assembly political declaration would be a “powerful signal that the global community is serious about non-communicable disease prevention and control,” argues the United for Self-Care Coalition, which includes the Global Self-Care Federation, International Self-Care Foundation and Imperial College London’s Self-Care Academic Research Unit.

Danes Get OTC Access To ED Treatment

 
• By Tom Gallen

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Perrigo Sees Growth Opportunities In Tariff Storm

 
• By Malcolm Spicer

As largest provider of private label/store brand OTCs with “100 plus molecules across 100% price point coverage,” CEO Patrick Lockwood-Taylor says Perrigo’s in position to capitalize as consumers become “more cautious” and look for lower-priced products.